Early Detection of Alzheimer’s Disease Through exRNA Biomarkers
Alzheimer’s Disease (AD), a progressive neurodegenerative disease, is estimated to affect around 50 million people worldwide. AD is most prevalent in North America and Western
Alzheimer’s Disease (AD), a progressive neurodegenerative disease, is estimated to affect around 50 million people worldwide. AD is most prevalent in North America and Western
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, and the Parkinson’s Foundation estimates that 1.2 million people in the United States will suffer
Last month, American pharmaceutical company Eli Lilly ended its fourth study investigating the effectiveness of solanezumab, a potential drug therapy for people with mild cognitive impairment
The 5xFAD mouse is a popular rodent model in the preclinical Alzheimer’s disease research community. Recently, research performed on 5xFAD mice benefited Shanghai-based company Green Valley’s
Recently, the Shanghai-based company Green Valley announced approval of their drug candidate Oligomannate for clinical use in mild to moderate Alzheimer’s disease (AD) in China.
Biomarkers are an emerging area of focus in neurodegenerative diseases. This new scrutiny has arisen because biomarkers may provide an important link between preclinical disease
QPS Neuropharmacology and the research group of Marcello Leopoldo from the University of Bari Aldo Moro, Italy, are collaborating on a funded research project related
Preclinical trials and studies of all kinds involve a number of different types of testing, including in vivo, in situ, in silico, and in vitro
Are you looking to explore Cerebral Amyloid Angiopathy (CAA) as an independent risk factor for cognitive dysfunction or Alzheimer’s disease? QPS Austria, one of the
Alzheimer’s Disease (AD), a progressive neurodegenerative disease, is estimated to affect around 50 million people worldwide. AD is most prevalent in North America and Western
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases, and the Parkinson’s Foundation estimates that 1.2 million people in the United States will suffer
Last month, American pharmaceutical company Eli Lilly ended its fourth study investigating the effectiveness of solanezumab, a potential drug therapy for people with mild cognitive impairment
The 5xFAD mouse is a popular rodent model in the preclinical Alzheimer’s disease research community. Recently, research performed on 5xFAD mice benefited Shanghai-based company Green Valley’s
Recently, the Shanghai-based company Green Valley announced approval of their drug candidate Oligomannate for clinical use in mild to moderate Alzheimer’s disease (AD) in China.
Biomarkers are an emerging area of focus in neurodegenerative diseases. This new scrutiny has arisen because biomarkers may provide an important link between preclinical disease
QPS Neuropharmacology and the research group of Marcello Leopoldo from the University of Bari Aldo Moro, Italy, are collaborating on a funded research project related
Preclinical trials and studies of all kinds involve a number of different types of testing, including in vivo, in situ, in silico, and in vitro
Are you looking to explore Cerebral Amyloid Angiopathy (CAA) as an independent risk factor for cognitive dysfunction or Alzheimer’s disease? QPS Austria, one of the
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields